Classe Jean-Marc, Asselain Bernard, Campion Loic, Berton Dominique, Frenel Jean-Sébastien, Lécuru Fabrice, Ferron Gwenael, Gladieff Laurence, Bourgin Charlotte, Loaec Cecile
Department of Surgery, Institut de Cancerologie de l'Ouest, Boulevard Professor Monod, 44805 Saint Herblain, France.
Faculty of Medicine, Nantes University, 1 Rue Gaston Veil, 44000 Nantes, France.
Cancers (Basel). 2021 Dec 30;14(1):172. doi: 10.3390/cancers14010172.
Hyperthermic intraperitoneal chemotherapy (HIPEC) is routinely used in the treatment of a first ovarian cancer relapse.
This systematic review, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, aimed to assess the quality of scientific proof of the survival benefits of HIPEC, using Medline and Google Scholar. Qualitative analysis using the Oxford CEBM Levels of Evidence 2011 grading is reported.
Of 469 articles identified, 23 were included; 15 based on series of patients treated with HIPEC without a control group, and 8 case control series of patients treated with or without HIPEC. The series without a control group showed median overall survival (OS) ranged from 23.5 to 63 months, highlighting a broad standard deviation. Considering the case control series, OS was significantly better in the HIPEC group in 5 studies, and similar in 1. The current review showed considerable heterogeneity and biases, with an Oxford Level of Evidence grading of 4 for 22 selected series and 2 for one.
There is no strong evidence to suggest efficacy of HIPEC in improving survival of patients treated for a first relapse of ovarian cancer due to the low quality of the data.
热灌注化疗（HIPEC）常用于首次卵巢癌复发的治疗。
本系统评价按照系统评价和Meta分析的首选报告项目指南，旨在通过Medline和谷歌学术评估HIPEC生存获益的科学证据质量。报告采用牛津循证医学中心2011年证据水平分级进行的定性分析。
在检索到的469篇文章中，纳入23篇；15篇基于接受HIPEC治疗的患者系列且无对照组，8篇为接受或未接受HIPEC治疗的患者病例对照系列。无对照组的系列研究显示中位总生存期（OS）为23.5至63个月，标准差较大。在病例对照系列中，5项研究显示HIPEC组的OS显著更好，1项研究显示两者相似。当前评价显示存在相当大的异质性和偏倚，22个入选系列的牛津证据水平分级为4级，1个为2级。
由于数据质量较低，没有有力证据表明HIPEC能提高首次复发卵巢癌患者的生存率。
